142 related articles for article (PubMed ID: 20846264)
1. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
Ali A; Furusato B; Ts'o PO; Lum ZP; Elsamanoudi S; Mohamed A; Srivastava S; Moul JW; Brassell SA; Sesterhenn IA; McLeod DG
Pathol Int; 2010 Oct; 60(10):667-72. PubMed ID: 20846264
[TBL] [Abstract][Full Text] [Related]
2. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
[TBL] [Abstract][Full Text] [Related]
3. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
4. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
5. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation.
Resel Folkersma L; Olivier Gómez C; San José Manso L; Veganzones de Castro S; Galante Romo I; Vidaurreta Lázaro M; de la Orden GV; Arroyo Fernández M; Díaz Rubio E; Silmi Moyano A; Maestro de Las Casas MA
Arch Esp Urol; 2010; 63(1):23-31. PubMed ID: 20157216
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
7. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
9. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy.
Stoffel JT; Topjian L; Libertino JA
BJU Int; 2005 Aug; 96(3):313-5. PubMed ID: 16042720
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
11. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
Jones TD; Koch MO; Bunde PJ; Cheng L
BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Davis JW; Nakanishi H; Kumar VS; Bhadkamkar VA; McCormack R; Fritsche HA; Handy B; Gornet T; Babaian RJ
J Urol; 2008 Jun; 179(6):2187-91; discussion 2191. PubMed ID: 18423725
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
[TBL] [Abstract][Full Text] [Related]
14. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy.
de Cremoux P; Ravery V; Podgorniak MP; Chevillard S; Toublanc M; Thiounn N; Tatoud R; Delmas V; Calvo T; Boccon-Gibod L
Eur Urol; 1997; 32(1):69-74. PubMed ID: 9266235
[TBL] [Abstract][Full Text] [Related]
15. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
16. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells predict survival in patients with metastatic prostate cancer.
Moreno JG; Miller MC; Gross S; Allard WJ; Gomella LG; Terstappen LW
Urology; 2005 Apr; 65(4):713-8. PubMed ID: 15833514
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells in solid tumor in metastatic and localized stages.
Maestro LM; Sastre J; Rafael SB; Veganzones SB; Vidaurreta M; Martín M; Olivier C; DE La Orden VB; Garcia-Saenz JA; Alfonso R; Arroyo M; Diaz-Rubio E
Anticancer Res; 2009 Nov; 29(11):4839-43. PubMed ID: 20032444
[TBL] [Abstract][Full Text] [Related]
19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
20. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
